Monoclonal antibodies which neutralize HIV-1 infection
US5854400A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 22, 1992 |
| Grant date | Dec 29, 1998 |
| Priority date | — |
| Expiry date | Sep 22, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Murine monoclonal antibodies and related products such as antibody fragments, immunotoxins, human and humanized antibodies are disclosed, all of which bind to the gp120 protein on the envelope of HIV-1. These antibodies and related products neutralize HIV-1. They inhibit the infection of T cells, and also inhibit syncytium formation. Further, the antibodies are preferably group-specific and neutralize various strains and isolates of HIV-1. These antibodies have a variety of uses, including the treatment of AIDS and ARC, the prevention of HIV-1 infection, as well as a diagnostic application, in that they can be used for assaying of unknown fluid samples for HIV-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.